Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Medical Oncology
Interventions: DRUG: BAY1161909|DRUG: Paclitaxel
Sponsor: Bayer